Global Aflibercept Drug Market

Aflibercept Drug Comprehensive Study by Application (Diabetic Macular Edoema (DME), Age-Related Macular Degeneration (AMD), Central Retinal Vein Occlusion (CRVO)), Distribution (Hospital Dispensary, Retail Pharmacy/Drug Outlets, Specialty Stores, Online Third-Party Sales), Dosage (Less than 5 mg, 5 - 10 mg, More than 10 mg) Players and Region - Global Market Outlook to 2026

Aflibercept Drug Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Aflibercept Drug Market Scope
In the developed world, age-related macular degeneration (AMD) is the main cause of significant visual loss in adults over the age of 65. Aflibercept, a colorectal cancer medication that is designed humanised anti-vascular endothelial growth factor (VEGF), has been linked to serious infections. Aflibercept is a protein that functions as a decoy receptor for all VEGF-A isoforms and placental growth factor. Because of its improved potency and duration of action, aflibercept may provide equal efficacy with fewer intravitreal injections and visits to the doctor. The value of a longer duration of action cannot be stressed for the patient with CRVO requiring monthly intraocular injections, as well as the health care system, which has seen spending on VEGF-inhibitors increase.

The Aflibercept Drug market study is segmented, by Application (Diabetic Macular Edoema (DME), Age-Related Macular Degeneration (AMD) and Central Retinal Vein Occlusion (CRVO)) and major geographies with country level break-up.

The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Research Analyst at AMA estimates that United States Players will contribute to the maximum growth of Global Aflibercept Drug market throughout the predicted period.

Bayer AG (Germany), Regeneron Pharmaceuticals (United States) and EagleBio (United States) are some of the key players that are part of study coverage.

About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a
preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from total available market.

Segmentation Overview
AMA Research has segmented the market of Global Aflibercept Drug market by Type, Application and Region.

On the basis of geography, the market of Aflibercept Drug has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).

On 13th August, 2019 - Regeneron Pharmaceuticals, Inc. Received FDA Approval for “Eylea” (Aflibercept) Injection Prefilled Syringe. In Relation to Vials, the 2 Mg Single-Dose Sterilised Prefilled Syringe Offers Physicians a Novel Approach to Deliver EYLEA That Needs Fewer Preparation Procedures. and On 10th February, 2020 - Bayer and Regeneron Pharmaceuticals Announced Phase III Trials of its New Aflibercept 8mg Formulation. The Trials Evaluate Prolonged Treatment Intervals with A Novel Aflibercept 8mg Formulation for Intravitreal Injection in People with Diabetic Macular Edoema (DME) and Wet Age-Related Macular Degeneration.


Market Trend
  • High Investments in Healthcare R&D

Market Drivers
  • Prevalence of Age-Related Macular Degeneration (AMD)
  • Rising Geriatric Population

Opportunities
  • Growth in Healthcare Infrastructure Across Emerging Regions
  • Ongoing Clinical Trials for Enhanced Efficacy

Restraints
  • Lack of Skilled Professionals

Challenges
  • Fierce Competitive Pressure


Key Target Audience
Aflibercept Drug Manufactures, New Entrants and Investors, Aflibercept Drug Distributors and Suppliers, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others

Report Objectives / Segmentation Covered

By Application
  • Diabetic Macular Edoema (DME)
  • Age-Related Macular Degeneration (AMD)
  • Central Retinal Vein Occlusion (CRVO)
By Distribution
  • Hospital Dispensary
  • Retail Pharmacy/Drug Outlets
  • Specialty Stores
  • Online Third-Party Sales

By Dosage
  • Less than 5 mg
  • 5 - 10 mg
  • More than 10 mg

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Prevalence of Age-Related Macular Degeneration (AMD)
      • 3.2.2. Rising Geriatric Population
    • 3.3. Market Challenges
      • 3.3.1. Fierce Competitive Pressure
    • 3.4. Market Trends
      • 3.4.1. High Investments in Healthcare R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Aflibercept Drug, by Application, Distribution, Dosage and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Aflibercept Drug (Value)
      • 5.2.1. Global Aflibercept Drug by: Application (Value)
        • 5.2.1.1. Diabetic Macular Edoema (DME)
        • 5.2.1.2. Age-Related Macular Degeneration (AMD)
        • 5.2.1.3. Central Retinal Vein Occlusion (CRVO)
      • 5.2.2. Global Aflibercept Drug by: Distribution (Value)
        • 5.2.2.1. Hospital Dispensary
        • 5.2.2.2. Retail Pharmacy/Drug Outlets
        • 5.2.2.3. Specialty Stores
        • 5.2.2.4. Online Third-Party Sales
      • 5.2.3. Global Aflibercept Drug by: Dosage (Value)
        • 5.2.3.1. Less than 5 mg
        • 5.2.3.2. 5 - 10 mg
        • 5.2.3.3. More than 10 mg
      • 5.2.4. Global Aflibercept Drug Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Aflibercept Drug: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bayer AG (Germany)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Regeneron Pharmaceuticals (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. EagleBio (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
  • 7. Global Aflibercept Drug Sale, by Application, Distribution, Dosage and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Aflibercept Drug (Value)
      • 7.2.1. Global Aflibercept Drug by: Application (Value)
        • 7.2.1.1. Diabetic Macular Edoema (DME)
        • 7.2.1.2. Age-Related Macular Degeneration (AMD)
        • 7.2.1.3. Central Retinal Vein Occlusion (CRVO)
      • 7.2.2. Global Aflibercept Drug by: Distribution (Value)
        • 7.2.2.1. Hospital Dispensary
        • 7.2.2.2. Retail Pharmacy/Drug Outlets
        • 7.2.2.3. Specialty Stores
        • 7.2.2.4. Online Third-Party Sales
      • 7.2.3. Global Aflibercept Drug by: Dosage (Value)
        • 7.2.3.1. Less than 5 mg
        • 7.2.3.2. 5 - 10 mg
        • 7.2.3.3. More than 10 mg
      • 7.2.4. Global Aflibercept Drug Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Aflibercept Drug: by Application(USD Million)
  • Table 2. Aflibercept Drug Diabetic Macular Edoema (DME) , by Region USD Million (2015-2020)
  • Table 3. Aflibercept Drug Age-Related Macular Degeneration (AMD) , by Region USD Million (2015-2020)
  • Table 4. Aflibercept Drug Central Retinal Vein Occlusion (CRVO) , by Region USD Million (2015-2020)
  • Table 5. Aflibercept Drug: by Distribution(USD Million)
  • Table 6. Aflibercept Drug Hospital Dispensary , by Region USD Million (2015-2020)
  • Table 7. Aflibercept Drug Retail Pharmacy/Drug Outlets , by Region USD Million (2015-2020)
  • Table 8. Aflibercept Drug Specialty Stores , by Region USD Million (2015-2020)
  • Table 9. Aflibercept Drug Online Third-Party Sales , by Region USD Million (2015-2020)
  • Table 10. Aflibercept Drug: by Dosage(USD Million)
  • Table 11. Aflibercept Drug Less than 5 mg , by Region USD Million (2015-2020)
  • Table 12. Aflibercept Drug 5 - 10 mg , by Region USD Million (2015-2020)
  • Table 13. Aflibercept Drug More than 10 mg , by Region USD Million (2015-2020)
  • Table 14. South America Aflibercept Drug, by Country USD Million (2015-2020)
  • Table 15. South America Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 16. South America Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 17. South America Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 18. Brazil Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 19. Brazil Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 20. Brazil Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 21. Argentina Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 22. Argentina Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 23. Argentina Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 24. Rest of South America Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 25. Rest of South America Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 26. Rest of South America Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 27. Asia Pacific Aflibercept Drug, by Country USD Million (2015-2020)
  • Table 28. Asia Pacific Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 29. Asia Pacific Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 30. Asia Pacific Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 31. China Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 32. China Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 33. China Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 34. Japan Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 35. Japan Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 36. Japan Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 37. India Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 38. India Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 39. India Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 40. South Korea Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 41. South Korea Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 42. South Korea Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 43. Taiwan Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 44. Taiwan Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 45. Taiwan Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 46. Australia Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 47. Australia Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 48. Australia Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 49. Rest of Asia-Pacific Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 50. Rest of Asia-Pacific Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 52. Europe Aflibercept Drug, by Country USD Million (2015-2020)
  • Table 53. Europe Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 54. Europe Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 55. Europe Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 56. Germany Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 57. Germany Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 58. Germany Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 59. France Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 60. France Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 61. France Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 62. Italy Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 63. Italy Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 64. Italy Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 65. United Kingdom Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 66. United Kingdom Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 67. United Kingdom Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 68. Netherlands Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 69. Netherlands Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 70. Netherlands Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 71. Rest of Europe Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 72. Rest of Europe Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 73. Rest of Europe Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 74. MEA Aflibercept Drug, by Country USD Million (2015-2020)
  • Table 75. MEA Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 76. MEA Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 77. MEA Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 78. Middle East Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 79. Middle East Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 80. Middle East Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 81. Africa Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 82. Africa Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 83. Africa Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 84. North America Aflibercept Drug, by Country USD Million (2015-2020)
  • Table 85. North America Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 86. North America Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 87. North America Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 88. United States Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 89. United States Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 90. United States Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 91. Canada Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 92. Canada Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 93. Canada Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 94. Mexico Aflibercept Drug, by Application USD Million (2015-2020)
  • Table 95. Mexico Aflibercept Drug, by Distribution USD Million (2015-2020)
  • Table 96. Mexico Aflibercept Drug, by Dosage USD Million (2015-2020)
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Aflibercept Drug: by Application(USD Million)
  • Table 101. Aflibercept Drug Diabetic Macular Edoema (DME) , by Region USD Million (2021-2026)
  • Table 102. Aflibercept Drug Age-Related Macular Degeneration (AMD) , by Region USD Million (2021-2026)
  • Table 103. Aflibercept Drug Central Retinal Vein Occlusion (CRVO) , by Region USD Million (2021-2026)
  • Table 104. Aflibercept Drug: by Distribution(USD Million)
  • Table 105. Aflibercept Drug Hospital Dispensary , by Region USD Million (2021-2026)
  • Table 106. Aflibercept Drug Retail Pharmacy/Drug Outlets , by Region USD Million (2021-2026)
  • Table 107. Aflibercept Drug Specialty Stores , by Region USD Million (2021-2026)
  • Table 108. Aflibercept Drug Online Third-Party Sales , by Region USD Million (2021-2026)
  • Table 109. Aflibercept Drug: by Dosage(USD Million)
  • Table 110. Aflibercept Drug Less than 5 mg , by Region USD Million (2021-2026)
  • Table 111. Aflibercept Drug 5 - 10 mg , by Region USD Million (2021-2026)
  • Table 112. Aflibercept Drug More than 10 mg , by Region USD Million (2021-2026)
  • Table 113. South America Aflibercept Drug, by Country USD Million (2021-2026)
  • Table 114. South America Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 115. South America Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 116. South America Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 117. Brazil Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 118. Brazil Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 119. Brazil Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 120. Argentina Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 121. Argentina Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 122. Argentina Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 123. Rest of South America Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 124. Rest of South America Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 125. Rest of South America Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 126. Asia Pacific Aflibercept Drug, by Country USD Million (2021-2026)
  • Table 127. Asia Pacific Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 128. Asia Pacific Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 129. Asia Pacific Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 130. China Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 131. China Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 132. China Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 133. Japan Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 134. Japan Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 135. Japan Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 136. India Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 137. India Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 138. India Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 139. South Korea Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 140. South Korea Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 141. South Korea Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 142. Taiwan Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 143. Taiwan Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 144. Taiwan Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 145. Australia Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 146. Australia Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 147. Australia Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 148. Rest of Asia-Pacific Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 149. Rest of Asia-Pacific Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 150. Rest of Asia-Pacific Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 151. Europe Aflibercept Drug, by Country USD Million (2021-2026)
  • Table 152. Europe Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 153. Europe Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 154. Europe Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 155. Germany Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 156. Germany Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 157. Germany Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 158. France Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 159. France Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 160. France Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 161. Italy Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 162. Italy Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 163. Italy Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 164. United Kingdom Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 165. United Kingdom Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 166. United Kingdom Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 167. Netherlands Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 168. Netherlands Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 169. Netherlands Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 170. Rest of Europe Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 171. Rest of Europe Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 172. Rest of Europe Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 173. MEA Aflibercept Drug, by Country USD Million (2021-2026)
  • Table 174. MEA Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 175. MEA Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 176. MEA Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 177. Middle East Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 178. Middle East Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 179. Middle East Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 180. Africa Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 181. Africa Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 182. Africa Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 183. North America Aflibercept Drug, by Country USD Million (2021-2026)
  • Table 184. North America Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 185. North America Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 186. North America Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 187. United States Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 188. United States Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 189. United States Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 190. Canada Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 191. Canada Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 192. Canada Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 193. Mexico Aflibercept Drug, by Application USD Million (2021-2026)
  • Table 194. Mexico Aflibercept Drug, by Distribution USD Million (2021-2026)
  • Table 195. Mexico Aflibercept Drug, by Dosage USD Million (2021-2026)
  • Table 196. Research Programs/Design for This Report
  • Table 197. Key Data Information from Secondary Sources
  • Table 198. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Aflibercept Drug: by Application USD Million (2015-2020)
  • Figure 5. Global Aflibercept Drug: by Distribution USD Million (2015-2020)
  • Figure 6. Global Aflibercept Drug: by Dosage USD Million (2015-2020)
  • Figure 7. South America Aflibercept Drug Share (%), by Country
  • Figure 8. Asia Pacific Aflibercept Drug Share (%), by Country
  • Figure 9. Europe Aflibercept Drug Share (%), by Country
  • Figure 10. MEA Aflibercept Drug Share (%), by Country
  • Figure 11. North America Aflibercept Drug Share (%), by Country
  • Figure 12. Global Aflibercept Drug share by Players 2020 (%)
  • Figure 13. BCG Matrix for key Companies
  • Figure 14. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 15. Bayer AG (Germany) Revenue: by Geography 2020
  • Figure 16. Regeneron Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 17. Regeneron Pharmaceuticals (United States) Revenue: by Geography 2020
  • Figure 18. EagleBio (United States) Revenue, Net Income and Gross profit
  • Figure 19. EagleBio (United States) Revenue: by Geography 2020
  • Figure 20. Global Aflibercept Drug: by Application USD Million (2021-2026)
  • Figure 21. Global Aflibercept Drug: by Distribution USD Million (2021-2026)
  • Figure 22. Global Aflibercept Drug: by Dosage USD Million (2021-2026)
  • Figure 23. South America Aflibercept Drug Share (%), by Country
  • Figure 24. Asia Pacific Aflibercept Drug Share (%), by Country
  • Figure 25. Europe Aflibercept Drug Share (%), by Country
  • Figure 26. MEA Aflibercept Drug Share (%), by Country
  • Figure 27. North America Aflibercept Drug Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bayer AG (Germany)
  • Regeneron Pharmaceuticals (United States)
  • EagleBio (United States)
Select User Access Type

Key Highlights of Report


Aug 2021 215 Pages 62 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Aflibercept Drug Market Quantitative research analysis
Global Aflibercept Drug Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a study that suits your business objectives.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2026.

Know More About Global Aflibercept Drug Market Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical Lactose Comprehensive Study by Type (Crystalline Monohydrate Lactose, Inhalation Lactose, Granulated Lactose, Spray Dried Lactose, Others), Application (Tablets Manufacturing, Capsule ...
$ 3350
Flu RNA Vaccines Comprehensive Study by Application (Hospitals, Emergency Departments, Clinics, Others), End Users (Adults, Kids), Sales (Hospitals, Retail Pharmacy Stores), Usages (Infectious Diseas...
$ 3500
Linezolid Drug Comprehensive Study by Application (Complex Skin or Skin Soft Tissue Infection (SSTI), Hospital-Acquired Pneumonia (HAP), Community-Acquired Pneumonia (CAP), Vancomycin-Resistant Enter...
$ 3750
Gossypol Drugs Comprehensive Study by Form (Tablet, Capsule, Others), Distribution (Hospital Dispensaries, Retail Pharmacies, Online Third-Party Sales) Players and Region - Global Market Outlook to 2...
$ 3500
Rare Dermatological Disease Treatment Comprehensive Study by Treatment (Corticosteroids, Immunosuppressants, Anti-inflammatory Agents, Antibiotics, Analgesics, Others), Indication (Systemic Sclerosis...
$ 3450
Liquid Filled Hard Capsule Comprehensive Study by Application (Drugs, Vitamins & Mineral, Amino Acids, Peptides & Proteins, Lipids, Others), End Users (Pharmaceutical & Biopharmaceutical Companies, N...
$ 3650